Tranexamic acid controlled-release

Drug Profile

Tranexamic acid controlled-release

Alternative Names: Lysteda; Tranexamic acid SR; Tranexamic acid sustained-release; XP-12B

Latest Information Update: 04 Jan 2013

Price : $50

At a glance

  • Originator Xanodyne Pharmaceuticals
  • Class Antifibrinolytics; Antihaemorrhagics; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Menorrhagia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Jan 2013 Generic equivalent approved in USA for Menorrhagia
  • 07 Oct 2010 Efficacy and safety data from a phase III trial (NCT003863080) in Menorrhagia released by Ferring Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top